SCHEDULE: Janus Henderson Discloses 10.7% Stake in Avidity Biosciences
Beneficial Ownership Report
Janus Henderson Group plc has filed an amended Schedule 13G, reporting a 10.7% beneficial ownership stake in Avidity Biosciences, Inc.
Summary
- Janus Henderson Group plc, a global asset manager, has filed an Amendment No. 3 to its Schedule 13G regarding its beneficial ownership in Avidity Biosciences, Inc.
- The reporting person, Janus Henderson Group plc, beneficially owns an aggregate of 14,522,915 shares of Avidity Biosciences' Common Stock.
- This ownership represents 10.7% of the class of securities.
- Janus Henderson Group plc holds shared voting power and shared dispositive power over all 14,522,915 shares.
- JHIUS, an indirect subsidiary of Janus Henderson, is deemed to be the beneficial owner of 14,292,315 shares, representing 10.5% of the class.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of beneficial ownership by an institutional investor and does not contain information that would inherently indicate a positive or negative sentiment towards the issuer's performance or prospects.
Positives
- A significant institutional investor, Janus Henderson Group plc, maintains a substantial 10.7% stake in Avidity Biosciences, which can be viewed as a vote of confidence in the company's long-term prospects.
Future Outlook
The filing does not contain any forward-looking statements or guidance from Avidity Biosciences or Janus Henderson Group plc regarding the issuer's future performance.
Management Comments
- Janus Henderson Group plc certifies that, to the best of its knowledge and belief, the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Avidity Biosciences.
Industry Context
Avidity Biosciences operates in the biotechnology sector, a field often characterized by significant institutional investment due to its potential for high growth and innovation. Janus Henderson Group plc is a global asset manager, and its substantial stake reflects typical institutional portfolio allocation strategies in specialized industries.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Internal Authorization | Janus Henderson Group plc executed a Power of Attorney on December 9, 2022, authorizing Kristin Mariani and Caroline Barotti to execute SEC filings on its behalf. | 12/09/2022 | This is an internal corporate governance measure for Janus Henderson Group plc, streamlining its compliance and reporting processes for regulatory filings. |
Stakeholder Impact
- Shareholders of Avidity Biosciences may view the continued significant ownership by a major institutional investor like Janus Henderson Group plc as a positive signal regarding the company's stability and potential.
Key Dates
| Date | Description |
|---|---|
| 12/09/2022 | Power of Attorney executed by Janus Henderson Group plc, appointing Kristin Mariani and Caroline Barotti as attorneys-in-fact for SEC filings. |
| 09/30/2025 | Date of event which requires the filing of this statement. |
| 11/14/2025 | Signature date of the Schedule 13G filing by Kristin Mariani on behalf of Janus Henderson Group plc. |
Keywords
Avidity Biosciences, Janus Henderson, institutional ownership, Schedule 13G, common stock, biotechnology, investment adviser, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.